PhD, University of Cincinnati, 2019, Medicine: Cancer and Cell Biology
Breast cancer is a leading cause of cancer-related deaths among women worldwide, with an estimated 268,000 new diagnoses and roughly 40,000 deaths occurring in the U.S. alone in the year 2019. Importantly, while breast cancers are categorized into distinct subtypes to dictate which treatment strategy to take, a key indicator of a patient's prognosis is whether or not the cancer has metastasized to distant organs. It is typically not the formation of the primary tumor, but the spread or metastasis of tumor cells that leads to patient mortality, and there is no cure for metastatic breast cancer once it occurs. Nearly two-thirds of all breast cancers express estrogen receptor (ER), and recent research in our laboratory has identified a key role for ER-coactivator Mediator Subunit 1 (MED1) and its two LxxLL motifs in HER2-mediated tumor onset, growth and lung metastasis. Herein, this thesis describes our work to isolate a pool of RNA aptamers that bind to MED1s LxxLL motifs to disrupt the ER/MED1 interaction. One such top RNA aptamer candidate, labeled MED1SP, was capable of selectively disrupting the ER/MED1 interaction while not affecting other ER coactivators like SRC and PGC1-ß. To deliver this MED1SP aptamer to breast cancer cells in vivo, we further incorporated MED1SP into a pRNA nanoparticle delivery system harboring a 3-way junction (3WJ) motif scaffold and a HER2-targeting RNA aptamer. The resultant pRNA-HER2-MED1SP nanoparticles were highly stable, and capable of being successfully delivered to and taken up by HER2-expressing breast cancer cells, where they significantly disrupted cell viability, ER-reporter and –endogenous gene expression, and migration and invasion capabilities. Importantly, when administered into orthotopic xenograft mouse models by I.V. injection, these nanoparticles specifically targeted orthotopically xenografted HER2-expressing tumors, where they dramatically decreased both tumor growth and lung metastasis, with no accumulation or hist (open full item for complete abstract)
Committee: Xiaoting Zhang Ph.D. (Committee Chair); Zalfa Abdelmalek Ph.D. (Committee Member); Jiajie Diao Ph.D. (Committee Member); Jun-Lin Guan Ph.D. (Committee Member); Elyse Lower M.D. (Committee Member)
Subjects: Oncology